News

The pooled analyses from Arcutis’ INTEGUMENT-1 and INTEGUMENT-2 studies were presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

Data from Arcutis’ STRATUM study was presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

The promising results were presented in a poster at the 2024 Winter Clinical Hawaii Dermatology Conference in Honolulu, Hawaii.

Keep up with the latest headlines in dermatology from the past week, including the rising demand for anti-aging products in young patients, eczema and mental health, and more.

ICYMI, this week we had articles about higher response rates were observed in HS patients treated with lutikizumab, a placebo-controlled study of cryosim-1 in prurigo nodularis, industry recommendations for drug products containing benzene, and more.

Ten posters at the Winter Clinical Hawaii and Maui Derm Conferences will showcase investigational data to expand treatment options for patients with atopic dermatitis and chronic hand eczema.

This is the first known meta-analysis to review the association between extent of smoking androgenetic alopecia.

Among the many sessions to be held at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

When examining Ezra’s skin, you note well-defined erythematous scaly plaques with well-defined, serpiginous, raised borders and yellow crusting on the anterior shins and forearms.

This article will discuss insights from research studies and offer specialized guidance aimed at dermatologists in hopes of fostering patient adherence in acne management.

The study explored the use of the ointment in an area of 100 cm squared.

Patients may be at risk of bone damage from topical corticosteroids as well as systemic corticosteroids, according to a large study from Taiwan.

Click here to answer our poll.

Identifying the underlying cause of hair thinning or loss is often a diagnosis of exclusion.

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Researchers found that high levels of AST and ALT in patients with acne taking oral isotretinoin was low in incidence.

Currently, some United States Pharmacopeia carbomer monographs allow unacceptable levels of benzene

To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists.

Researchers say that application of these findings in clinical settings could enhance treatment optimization.

The integration of digital tools, including telemedicine, into routine clinical care is not without its hurdles.

In this week’s Pointers With Portela, the 208SkinDoc reviews 7 different methods to treat acne without isotretinoin.

Winter Editor in Chief Christopher Bunick, MD, PhD, looks ahead to a year of dermatology innovations with a reflection on meaningful advances from 2023.

Researchers said this data is demonstrative of VYN201's positive effects on multiple vitiligo-related biomarkers.

Study findings suggest that Lavandula species, with their historical use in folk medicine, could emerge as valuable additions to AD treatment regimens. However, it's crucial to note that the efficacy of these oils is concentration-dependent.

Test your knowledge and explore a recent study on the relationship between alcohol consumption and skin diseases, including atopic dermatitis.

Researchers compared the quality of life, anxiety, depression, sleep disturbance, and other associated factors between patients with alopecia areata and vitiligo.

A randomized, placebo-controlled trial of the selective transient receptor potential melastatin 8 agonist explored its efficacy and safety in PN.

Dermatology Times is excited to ring in 2024 with a fresh perspective to amplify our impact, foster creativity, and deliver even more exceptional, compelling content to you—our cherished audience.

This week’s collection of the latest dermatologic studies covers ligelizumab for the treatment of chronic spontaneous urticaria, AI for the early detection of skin cancer, blood pressure monitoring for minoxidil therapy in alopecia patients, and aminolevulinic acid 20% solution plus blue light PDT for the treatment of AKs.